---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-25-018392"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2025-11-21T23:59:59+00:00"
generated_at: "2026-05-16T17:35:54.257011+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tonix Pharmaceuticals increases ATM equity offering capacity from $150M to $400M

## Summary
- Sales Agreement with A.G.P./Alliance Global Partners amended to raise maximum aggregate offering price to $400M from $150M.
- Amendment dated November 21, 2025; shares to be sold through at-the-market (ATM) issuance.
- Company filed legal opinion from Brownstein Hyatt Farber Schreck on share legality.
- Fundraising capacity more than doubled; no stated use of proceeds in the filing.

## SEC filing metadata
- accession: 0001999371-25-018392
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2025-11-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937125018392/0001999371-25-018392-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937125018392/tnxp-8k_112125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-25-018392
- JSON: https://secwatch.observer/filing/0001999371-25-018392.json
- Plain text: https://secwatch.observer/filing/0001999371-25-018392.txt

## Key facts
- Material Agreements
  Tonix Pharmaceuticals Holding Corp. amended Sales Agreement with A.G.P./Alliance Global Partners (effective 2025-11-21).
  - Action: amendment
  - Agreement: atm program
  - Counterparty: A.G.P./Alliance Global Partners
  - Effective: 2025-11-21
  source text: On November 21, 2025, Tonix Pharmaceuticals Holding Corp. (the “Company”) amended its Sales Agreement with A.G.P./Alliance Global Partners, dated as of June 11, 2025 (as amended, the “Sales Agreement”), to allow for an increase to the maximum aggregate offering price of shares issuable under the Sales Agreement (the “Amendment”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1430306/000199937125018392/0001999371-25-018392-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.